Targeting gene of insulin-like growth factor type I (IGF-I) on in vitro model of A549 cell line with triple-helix approach. Perspectives of gene therapy in non-small cell lung (NSCLC) cancer

P. Kopinski, J. Tujakowski, K. Bartczak, J. Golinska, A. Szpechcinski, P. Jarocki (Bydgoszcz, Krakow, Poland)

Source: Annual Congress 2006 - Biology and prognostic factors
Session: Biology and prognostic factors
Session type: Poster Discussion
Number: 2296
Disease area: Thoracic oncology

Congress or journal article abstract

Rating: 0
You must login to grade this presentation.

Share or cite this content

Citations should be made in the following way:
P. Kopinski, J. Tujakowski, K. Bartczak, J. Golinska, A. Szpechcinski, P. Jarocki (Bydgoszcz, Krakow, Poland). Targeting gene of insulin-like growth factor type I (IGF-I) on in vitro model of A549 cell line with triple-helix approach. Perspectives of gene therapy in non-small cell lung (NSCLC) cancer. Eur Respir J 2006; 28: Suppl. 50, 2296

You must login to share this Presentation/Article on Twitter, Facebook, LinkedIn or by email.

Member's Comments

No comment yet.
You must Login to comment this presentation.


Related content which might interest you:
Specific plasmids encoding shRNA molecules directed against growth factor receptors in cell proliferation inhibition and induction phenotype changes relevant to enhancement of anti-tumor immunity. Model of human non-small (NSCLC) and small (SCLC) cell lung cancer lines
Source: Annual Congress 2010 - Pathology of lung cancer
Year: 2010

Inhibition of insulin-like growth factor type I (IGF-I) gene in A549 human lung cancer cell line enhances cell apoptosis and causes phenotype changes relevant to increased tumor susceptibility to immune system
Source: Eur Respir J 2007; 30: Suppl. 51, 715s
Year: 2007

Bevacizumab (Avastin®) aerosol therapy (AT) inhibits primary and metastatic tumor growth in a murine model with human non-small cell lung cancer (NSCLC)
Source: Annual Congress 2012 - Treatment of lung cancer
Year: 2012


Increased vascular-endothelial growth factor a (VEGF-A) expression and response to angiogenesis inhibitor erlotinib in non-small-cell lung cancer (NSCLC) – hint for a new predictive marker?
Source: Annual Congress 2007 - Therapeutic approaches in thoracic oncology
Year: 2007


Genetic profiling and epidermal growth factor receptor-directed therapy in nonsmall cell lung cancer
Source: Eur Respir J 2011; 37: 183-193
Year: 2011



Efficacy of Afatinib, Erlotinib, and Gefitinib on epidermal growth factor receptor (EGFR) mutant non-small cell lung cancer (NSCLC) patients with brain metastasis: a network meta-analysis
Source: International Congress 2018 – Lung cancer: modern therapies and beyond
Year: 2018

A blood-based test for epidermal growth factor receptor mutations in patients with non-small cell lung cancer
Source: Annual Congress 2008 - Therapy in thoracic oncology
Year: 2008




Epidermal growth factor receptor (EGFR) expression in operable non-small cell lung cancer and its correlation with survival
Source: Annual Congress 2009 - Genetics in the smokers corner: from inflammation in smokers via COPD to cancer
Year: 2009


The prognostic value of serum epidermal growth factor receptor (EGFR) levels in patients with non-small cell lung cancer
Source: Eur Respir J 2004; 24: Suppl. 48, 674s
Year: 2004

The challenge of targeting EGFR: experience with gefitinib in nonsmall cell lung cancer
Source: Eur Respir Rev 2010 19: 186-196
Year: 2010



Nationwide real-world cohort study of first line TKI treatment in epidermal growth factor receptor mutated non-small cell lung cancer.
Source: Virtual Congress 2020 – Real-world data and registries of thoracic oncology
Year: 2020


Epidermal growth factor receptor (EGFR) expression in non-small cell lung carcinoma (NSCLC) and survival
Source: International Congress 2015 – Lung cancer: prognostic factors and features of oncogene-driven tumours
Year: 2015


A prospective phase II study of gefitinib for chemo-naïve patients with advanced non-small cell lung cancer with epidermal growth factor receptor gene mutations
Source: Annual Congress 2006 - Lung cancer treatment
Year: 2006


Epidermal growth factor receptor mutation status in advanced non-small cell lung cancer: A single institution experience
Source: Annual Congress 2012 - New biomarkers for lung cancer
Year: 2012

Epithelial growth factor receptor (EGFR) mutation status and the treatment of non-small cell lung cancer (NSCLC): A population based quality assurance analysis
Source: International Congress 2015 – Quality management in lung cancer
Year: 2015


Clinical features associated with epidermal growth factor receptor and K-RAS gene mutations in non-small cell lung cancer
Source: Eur Respir J 2006; 28: Suppl. 50, 811s
Year: 2006

Expression of vascular endothelial growth factor (VEGF) and association with lymphangiogenesis in non small cell (NSCLC) and small cell lung carcinomas (SCLC)
Source: Eur Respir J 2006; 28: Suppl. 50, 386s
Year: 2006

Inhibition of the effect of epidermal growth factor (EGF) on lung cancer cells. The use of plasmids encoding specific siRNA molecules
Source: International Congress 2015 – Biomarkers, immunology and molecular pathology of lung cancer
Year: 2015

Phenotype pattern of human non-small cell lung cancer (NSCLC) model line in immune escape phenomenon. Effect of transfection with plasmids encoding specific anti-EGFR1 and anti-HER2/neu short hairpin (SH)RNA sequences
Source: Annual Congress 2009 - Basic science and lung cancer
Year: 2009


Expression of tumor necrosis factor receptor 2 in human non-small cell lung cancer and its role as a potential prognostic biomarker
Source: International Congress 2019 – Biology of lung cancer
Year: 2019